S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
NYSE:ZTS

Zoetis - ZTS Stock Forecast, Price & News

$165.18
-3.06 (-1.82%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$164.50
$167.69
50-Day Range
$142.47
$168.24
52-Week Range
$124.15
$205.30
Volume
1.83 million shs
Average Volume
2.16 million shs
Market Capitalization
$76.99 billion
P/E Ratio
37.71
Dividend Yield
0.89%
Price Target
$215.17

Zoetis MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
30.3% Upside
$215.17 Price Target
Short Interest
Healthy
0.78% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-4.66
Upright™ Environmental Score
News Sentiment
0.57mentions of Zoetis in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
10.27%
From $4.87 to $5.37 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

139th out of 1,055 stocks

Pharmaceutical Preparations Industry

56th out of 519 stocks


ZTS stock logo

About Zoetis (NYSE:ZTS) Stock

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

ZTS Stock News Headlines

UTHR vs. ZTS: Which Stock Is the Better Value Option?
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Brokerages Set Zoetis Inc. (NYSE:ZTS) Target Price at $215.17
Zoetis (NYSE:ZTS) Shares Gap Up to $166.75
Zoetis (ZTS) Shares Cross Below 200 DMA
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Zoetis Is An Awesome Dividend Growth Stock
Why Zoetis Stock Lost 40% in 2022
It's A Great Time To Buy Zoetis Shares
Is Zoetis Stock a Buy?
Zoetis' (NYSE:ZTS) Dividend Will Be Increased To $0.375
Calculating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
See More Headlines
Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

ZTS Company Calendar

Ex-Dividend for 12/1 Dividend
10/31/2022
Last Earnings
11/03/2022
Dividend Payable
12/01/2022
Ex-Dividend for 3/1 Dividend
1/19/2023
Today
1/28/2023
Next Earnings (Confirmed)
2/14/2023
Dividend Payable
3/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
98978V10
Employees
12,100
Year Founded
2012

Price Target and Rating

Average Stock Price Forecast
$215.17
High Stock Price Forecast
$248.00
Low Stock Price Forecast
$180.00
Forecasted Upside/Downside
+30.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$2.04 billion
Pretax Margin
32.10%

Debt

Sales & Book Value

Annual Sales
$7.78 billion
Cash Flow
$5.58 per share
Book Value
$9.60 per share

Miscellaneous

Free Float
465,513,000
Market Cap
$76.99 billion
Optionable
Optionable
Beta
0.73

Social Links


Key Executives

  • Kristin C. PeckKristin C. Peck
    Chief Executive Officer & Director
  • Roxanne LaganoRoxanne Lagano
    Chief Human Resources Officer
  • Wetteny JosephWetteny Joseph
    CFO, EVP & Head-Business Development
  • Robert J. Polzer
    Executive VP, President-Research & Development
  • Wafaa Mamilli
    Chief Digital & Technology Officer













ZTS Stock - Frequently Asked Questions

Should I buy or sell Zoetis stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZTS shares.
View ZTS analyst ratings
or view top-rated stocks.

What is Zoetis' stock price forecast for 2023?

7 Wall Street analysts have issued 1-year price targets for Zoetis' stock. Their ZTS share price forecasts range from $180.00 to $248.00. On average, they predict the company's stock price to reach $215.17 in the next twelve months. This suggests a possible upside of 30.3% from the stock's current price.
View analysts price targets for ZTS
or view top-rated stocks among Wall Street analysts.

How have ZTS shares performed in 2023?

Zoetis' stock was trading at $146.55 at the beginning of the year. Since then, ZTS shares have increased by 12.7% and is now trading at $165.18.
View the best growth stocks for 2023 here
.

When is Zoetis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023.
View our ZTS earnings forecast
.

How can I listen to Zoetis' earnings call?

Zoetis will be holding an earnings conference call on Tuesday, February 14th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) released its quarterly earnings results on Thursday, November, 3rd. The company reported $1.21 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.24 by $0.03. The business earned $2 billion during the quarter, compared to analysts' expectations of $2.08 billion. Zoetis had a net margin of 25.82% and a trailing twelve-month return on equity of 48.41%. The company's revenue was up .6% on a year-over-year basis. During the same period in the prior year, the business earned $1.25 earnings per share.
Read the conference call transcript
.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis announced a quarterly dividend on Thursday, December 8th. Investors of record on Friday, January 20th will be paid a dividend of $0.375 per share on Wednesday, March 1st. This represents a $1.50 annualized dividend and a dividend yield of 0.91%. The ex-dividend date of this dividend is Thursday, January 19th. This is a positive change from the stock's previous quarterly dividend of $0.33.
Read our dividend analysis for ZTS
.

Is Zoetis a good dividend stock?

Zoetis (NYSE:ZTS) pays an annual dividend of $1.50 per share and currently has a dividend yield of 0.89%. The company has been increasing its dividend for 9 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 34.25%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ZTS will have a dividend payout ratio of 27.93% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ZTS.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis updated its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share guidance of $4.83-$4.90 for the period, compared to the consensus earnings per share estimate of $5.00. The company issued revenue guidance of $8.00 billion-$8.07 billion, compared to the consensus revenue estimate of $8.26 billion.

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Who are Zoetis' major shareholders?

Zoetis' stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.19%), Congress Asset Management Co. MA (0.14%), New York State Teachers Retirement System (0.11%), Natixis Advisors L.P. (0.11%), AKO Capital LLP (0.08%) and Strs Ohio (0.07%). Insiders that own company stock include Catherine A Knupp, Glenn David, Gregory Norden, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Robert Edward Kelly, Robert W Scully, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends
.

How do I buy shares of Zoetis?

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $165.18.

How much money does Zoetis make?

Zoetis (NYSE:ZTS) has a market capitalization of $76.99 billion and generates $7.78 billion in revenue each year. The company earns $2.04 billion in net income (profit) each year or $4.38 on an earnings per share basis.

How many employees does Zoetis have?

The company employs 12,100 workers across the globe.

Does Zoetis have any subsidiaries?
The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Holding Limited, Abaxis Europe GmbH, Abaxis Holding GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma (Bermuda) LLC, Alpharma (Luxembourg) S.A.R.L. y Compania Limitada, Alpharma (Luxembourg) S.àr.l., Alpharma Animal Health (Hong Kong) Co. Limited, Alpharma Animal Health Company, Alpharma Euro Holdings LLC, Alpharma Holdings (Barbados) SRL, Alpharma LLC, Alpharma do Brasil Ltda., Bovigen, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Mikjan Corporation, NVIP Pty Ltd, Nexvet, Nexvet Australia Pty Ltd, Nordic Fish Tech AB, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PHARMAQ LTD, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS Technika SpA, Pharmaq Analytiq AS, Pharmaq CA Panama Inc., Pharmaq Fishteq AS, Pharmaq Holding AS, Pharmaq Settvac AS, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Platinum Performance, Platinum Performance Inc., Platinum Performance Nutrition Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics LLC, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis (Thailand) Limited, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark Aps, Zoetis Deutschland GmbH, Zoetis Egypt Import LLC, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management (Shanghai) Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis International Services, Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Lab Holdings LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa (Pty) Ltd., Zoetis Spain S.L., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Taiwan Limited, Zoetis Treasury Center BVBA, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o..
Read More
How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The official website for the company is www.zoetis.com. The company can be reached via phone at (973) 822-7000, via email at steve.frank@zoetis.com, or via fax at 302-655-5049.

This page (NYSE:ZTS) was last updated on 1/28/2023 by MarketBeat.com Staff